Media stories about Celldex Therapeutics (NASDAQ:CLDX) have been trending somewhat positive on Sunday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Celldex Therapeutics earned a news impact score of 0.08 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 47.5554748736371 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the headlines that may have impacted Accern Sentiment’s analysis:

Several brokerages recently issued reports on CLDX. Cowen restated a “hold” rating on shares of Celldex Therapeutics in a research note on Thursday. HC Wainwright set a $2.00 price target on Celldex Therapeutics and gave the company a “buy” rating in a research note on Thursday. Zacks Investment Research upgraded Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 price target on the stock in a research note on Tuesday, June 19th. Jefferies Financial Group restated a “hold” rating on shares of Celldex Therapeutics in a research note on Friday. Finally, ValuEngine upgraded Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $3.75.

Shares of CLDX stock traded down $0.02 during trading hours on Friday, hitting $0.43. The company had a trading volume of 1,413,369 shares, compared to its average volume of 1,318,902. Celldex Therapeutics has a 12 month low of $0.41 and a 12 month high of $3.26. The firm has a market cap of $72.32 million, a P/E ratio of -0.53 and a beta of 2.36.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.03. Celldex Therapeutics had a negative return on equity of 47.40% and a negative net margin of 1,159.26%. The company had revenue of $2.76 million for the quarter, compared to analyst estimates of $2.70 million. research analysts expect that Celldex Therapeutics will post -0.51 earnings per share for the current fiscal year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma.

Featured Article: What is the NASDAQ?

Insider Buying and Selling by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.